Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

AstraZeneca, Daiichi to jointly commercialize constipation drug Movantik in US AstraZeneca has entered into a co-commercialization agreement with the US unit of Daiichi Sankyo for distribution of its constipation drug, Movantik (naloxegol), a first-in-class once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA). Contract Research & Services > Contract Services > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

CASI gets CFDA approval to conduct Phase II trial of ENMD-2076 to treat OCCC
By PBR Staff Writer
US-based CASI Pharmaceuticals has received approval from the China Food and Drug Administration (CFDA) to conduct a global Phase II clinical trial of ENMD-2076, an orally-active, Aurora A/angiogenic kinase inhibitor, in patients with ovarian clear cell carcinoma (OCCC).
News
PledPharma reports positive top-line Phase IIb trial results of colorectal cancer drug PledOx
By PBR Staff Writer
Swedish pharmaceutical company PledPharma has reported top-line results from a Phase IIb trial (PLIANT) of its drug candidate PledOx in patients with advanced colorectal cancer.
News

Contract Research

Merck, American Diabetes Association partner to educate adults with diabetes
By PBR Staff Writer
Merck has entered into collaboration with the American Diabetes Association (ADA) to educate adults with diabetes about their increased risk for potentially serious health problems, including pneumococcal pneumonia, influenza (flu) and hepatitis B.
News
AstraZeneca, Harvard Stem Cell Institute enter five-year diabetes research collaboration
By PBR Staff Writer
AstraZeneca has signed a five-year collaboration deal with the Harvard Stem Cell Institute (HSCI), under which the parties will investigate adapting a technique to create human beta cells from stem cells for use in finding new treatments for diabetes.
News

Contract Services

Signum out-licenses SIG990 to Dermata to develop new topical treatment for rosacea
By PBR Staff Writer
US-based biotechnology firm Signum Dermalogix has out-licensed SIG990, a new anti-inflammatory compound, to Dermata Therapeutics for the development of a topical product to treat patients with rosacea, a chronic skin condition.
News
Can-Fite inks distribution deal with Cipher for CF101 in Canada
By PBR Staff Writer
Israel-based Can-Fite BioPharma has signed a distribution agreement with Canada-based Cipher Pharmaceuticals for the distribution of CF101, an A3 adenosine receptor agonist, designed to treat moderate to severe psoriasis and rheumatoid arthritis in the Canadian market.
News